|
| 38086008 | CML and the WHO: Why? | J Clin Oncol | 2024 |
| 36938892 | Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia. | Leuk Lymphoma | 2023 |
| 37670560 | Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia. | Eur J Haematol | 2023 |
| 37813298 | Clinical Validation of FusionPlex RNA Sequencing and Its Utility in the Diagnosis and Classification of Hematologic Neoplasms. | J Mol Diagn | 2023 |
| 37339483 | Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML. | Blood Adv | 2023 |
| 36547666 | Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia. | Clin Cancer Res | 2023 |
| 34780648 | MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis. | Blood | 2022 |
| 35740603 | Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms. | Cancers (Basel) | 2022 |
| 35511672 | Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. | Haematologica | 2022 |
| 34931301 | Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia. | Cancer | 2022 |
| 34491344 | Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. | J Natl Cancer Inst | 2022 |
| 33203990 | AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth. | Oncogene | 2021 |
| 33180106 | Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. | JAMA Oncol | 2021 |
| 31018977 | The vascular bone marrow niche influences outcome in chronic myeloid leukemia <i>via</i> the E-selectin - SCL/TAL1 - CD44 axis. | Haematologica | 2020 |
| 34109316 | An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia. | Nat Cancer | 2020 |
| 32077361 | Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. | Leuk Lymphoma | 2020 |
| 33275713 | First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia? | Hematology Am Soc Hematol Educ Program | 2020 |
| 32886902 | Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 33022644 | Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 31586148 | Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. | Leukemia | 2020 |
| 30635626 | The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia. | Leukemia | 2019 |
| 31145836 | Physical proximity and functional cooperation of glycoprotein 130 and glycoprotein VI in platelet membrane lipid rafts. | J Thromb Haemost | 2019 |
| 30409798 | Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. | Haematologica | 2019 |
| 29298978 | A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. | Nat Commun | 2018 |
| 30074259 | Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. | Am J Hematol | 2018 |
| 30545997 | Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2018 |
| 29609532 | Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. | BMC Cancer | 2018 |
| 29463550 | Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. | Clin Cancer Res | 2018 |
| 27048866 | Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia. | Sci Rep | 2016 |
| 27908736 | CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. | Cancer Cell | 2016 |
| 27511899 | miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. | Pediatr Blood Cancer | 2016 |
| 26800237 | Small, abnormal B lymphoid blast populations in chronic myelogenous leukemia at diagnosis: Does this finding indicate an accelerated course? | Cytometry B Clin Cytom | 2016 |
| 27083332 | Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. | Lancet Oncol | 2016 |
| 25713434 | Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. | J Clin Oncol | 2015 |
| 26644403 | Deregulated KLF4 Expression in Myeloid Leukemias Alters Cell Proliferation and Differentiation through MicroRNA and Gene Targets. | Mol Cell Biol | 2015 |
| 26688487 | Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. | Lancet Haematol | 2015 |
| 26212080 | Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. | Cell Stem Cell | 2015 |
| 25860293 | Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. | Blood Cancer J | 2015 |
| 24487275 | Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. | Nat Genet | 2014 |
| 23967110 | The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia. | PLoS One | 2013 |
| 24319180 | Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider? | Hematology Am Soc Hematol Educ Program | 2013 |
| 24319179 | Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice. | Hematology Am Soc Hematol Educ Program | 2013 |
| 24086639 | MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells and normal hematopoietic progenitors. | PLoS One | 2013 |
| 22296787 | Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data. | Bioinformatics | 2012 |
| 21158719 | The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells. | Curr Cancer Drug Targets | 2011 |
| 21873548 | Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. | Blood | 2011 |
| 21465636 | Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. | Pediatr Blood Cancer | 2011 |
| 20376086 | Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. | Leukemia | 2010 |
| 20639863 | Regulation of myeloid leukaemia by the cell-fate determinant Musashi. | Nature | 2010 |
| 18615105 | Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. | Leukemia | 2009 |